Adolescent psychopharmacology: evidence base and prescribing considerations

This reference summarizes the evidence base for adolescent psychopharmacology across the major medication classes used in clinical practice. It is intended for clinicians, trainees, and advanced practice providers prescribing in adolescent populations.

SSRIs in adolescents

Indications: anxiety disorders (GAD, social anxiety, panic, OCD, specific phobia), major depressive disorder, OCD, PTSD, and selected other indications.

Adolescent-specific evidence base:

• CAMS (Walkup et al. 2008): sertraline 55 percent response, CBT 60 percent, combination 81 percent, placebo 24 percent in pediatric anxiety.
• TADS (2004): fluoxetine 60.6 percent response, CBT 43.2 percent, combination 71.0 percent, placebo 34.8 percent in adolescent depression.
• POTS (2004): sertraline 21.4 percent remission, CBT 39.3 percent, combination 53.6 percent in pediatric OCD.
• Cipriani 2016 network meta-analysis: only fluoxetine showed statistically significant efficacy over placebo in pediatric depression network analysis.

FDA-approved adolescent indications:

• Fluoxetine: depression (8+), OCD (7+).
• Sertraline: OCD (6+).
• Escitalopram: depression (12+).
• Fluvoxamine: OCD (8+).

Dosing considerations:

• Fluoxetine: starting dose 10 mg, target 20 to 40 mg, max 80 mg.
• Sertraline: starting dose 12.5 to 25 mg, target 50 to 200 mg.
• Escitalopram: starting dose 5 mg, target 10 to 20 mg.
• Slow titration improves tolerability; activation effects more common in younger patients.

Monitoring:

• Suicidality screening at baseline and follow-up (C-SSRS or equivalent), especially during the first 4 to 8 weeks per the black-box warning.
• Mood activation, irritability, sleep changes.
• Weight at routine visits.
• Sexual side effects in age-appropriate conversations.

Stimulants in adolescents

Indications: ADHD across all presentations.

Evidence base:

• MTA (1999) and follow-up reports: 60 to 70 percent response to optimized stimulant treatment; combined treatment with behavioral therapy outperformed either alone on multiple functional outcomes.
• Multiple subsequent RCTs across formulations and age ranges.
• AAP 2019 guideline (reaffirmed 2024): first-line pharmacotherapy for school-age and adolescent ADHD.

Common formulations and FDA pediatric ages:

• Methylphenidate IR (6+), Ritalin LA (6+), Concerta (6+), Daytrana patch (6+), Quillivant XR (6+), Cotempla XR-ODT (6+).
• Amphetamine: Adderall (3+), Adderall XR (6+), Vyvanse (6+), Mydayis (13+), Dyanavel XR (6+).
• Combination of amphetamine and methylphenidate is generally avoided.

Dosing principles:

• Start low, titrate to clinical response, monitor side effects.
• Different patients respond to methylphenidate vs amphetamine class; trial of both may be appropriate when first class is suboptimal.
• Long-acting formulations preferred for school-age and adolescent patients for school-day coverage.

Monitoring:

• Cardiovascular: blood pressure and heart rate at baseline and follow-up. EKG only when personal or family history suggests cardiac risk.
• Growth: height and weight at routine follow-ups; tracking trajectory for deviation from expected.
• Sleep: insomnia common, often dose- or timing-related.
• Appetite suppression: common, often manageable with timing adjustments.

Non-stimulant ADHD medications

Atomoxetine. Norepinephrine reuptake inhibitor. FDA-approved 6+. 4 to 8 weeks to full effect. Useful for comorbid anxiety, substance use concerns, or stimulant intolerance. Hepatotoxicity warning, suicidality warning.

Guanfacine ER (Intuniv). Alpha-2 adrenergic agonist. FDA-approved 6 to 17. Useful for ADHD with hyperactivity, sleep issues, or aggression. Sedation common, often improves with continued treatment. Blood pressure monitoring.

Clonidine ER (Kapvay). Alpha-2 agonist. FDA-approved 6 to 17. Similar profile to guanfacine; sometimes used for ADHD-related sleep disruption.

Viloxazine (Qelbree). Norepinephrine reuptake inhibitor. FDA-approved 6+. Newer agent. Suicidality warning.

Atypical antipsychotics in adolescents

FDA-approved adolescent indications:

• Risperidone: schizophrenia (13+), bipolar I (10+), autism irritability (5+).
• Aripiprazole: schizophrenia (13+), bipolar I (10+), autism irritability (6+), Tourette's (6+).
• Olanzapine: schizophrenia (13+), bipolar I (13+).
• Quetiapine: schizophrenia (13+), bipolar I (10+, manic episodes).
• Lurasidone: schizophrenia (13+), bipolar I depression (10+).
• Asenapine: bipolar I (10+).
• Paliperidone: schizophrenia (12+).

Off-label adolescent uses:

• Severe disruptive behavior or aggression (often risperidone, aripiprazole)
• Augmentation in treatment-resistant depression (limited evidence)
• PTSD adjunctive treatment

Metabolic monitoring (per AACAP):

• Fasting glucose and lipid panel: baseline, 12 weeks, then quarterly.
• Weight: every visit.
• Blood pressure: every visit.
• Prolactin if symptomatic.
• HbA1c if any glucose abnormality.
• AIMS for tardive movement assessment.

Mood stabilizers in adolescents

Lithium. FDA-approved for bipolar I 12+. Therapeutic level 0.6 to 1.2 mEq/L (acute), 0.6 to 0.8 maintenance. Monitor: lithium level, TSH, BUN/creatinine, electrolytes, urinalysis. Drug-drug interactions significant (NSAIDs, ACE inhibitors, thiazides).

Valproate (Depakote). Off-label in pediatric bipolar. Therapeutic level 50 to 125 mcg/mL. Monitor: valproate level, LFTs, CBC with platelets, lipase. Black-box warnings: hepatotoxicity, pancreatitis, teratogenicity (significant for adolescent females of reproductive potential).

Lamotrigine (Lamictal). Off-label in pediatric bipolar maintenance. Slow titration required to reduce SJS/TEN risk. Monitor clinically; routine blood level not required.

Carbamazepine. Less commonly used; complex pharmacokinetics with auto-induction. HLA-B*1502 testing for patients of Asian descent (SJS/TEN risk).

Treatment-resistant pathways

Treatment-resistant adolescent depression (TORDIA framework):

1. Failure of adequate first SSRI trial (8 to 12 weeks at therapeutic dose).
2. Switch to second SSRI plus CBT, OR switch to venlafaxine plus CBT (TORDIA: 54.8 percent response with combination vs 40.5 percent with medication switch alone).
3. Monotherapy switches without CBT generally underperform.
4. Beyond second-line failure: atypical antipsychotic augmentation (limited adolescent data), lithium augmentation, MAOIs in select cases, ECT, TMS at specialty centers.

Treatment-resistant adolescent anxiety:

1. Failure of CBT and adequate SSRI trial.
2. Switch SSRI or augment with second agent (alpha-2 agonist, buspirone, low-dose atypical for severe cases).
3. ERP for OCD presentations.

Treatment-resistant adolescent OCD:

1. POTS framework: combined CBT plus SSRI as first-line.
2. Optimize SSRI (higher doses than for depression often required).
3. Switch SSRI or augment with low-dose atypical antipsychotic.
4. Specialty referral for severe treatment-resistant cases (deep brain stimulation, intensive ERP programs).

Operational considerations

Informed consent for adolescent prescribing. Document diagnosis, alternative treatments considered, expected benefits, common and serious side effects, monitoring plan, treatment duration considerations, off-label status when applicable.

Confidentiality framing. Establish at the start of treatment what is and isn't shared with parents. Standard carve-outs: acute suicidality with intent or plan, intent to harm others, current abuse, severe substance-related danger.

Polypharmacy considerations. Combination treatment is appropriate in specific scenarios but should have explicit clinical rationale. Each agent should target a specific symptom or diagnosis.

Discontinuation planning. Build expected course of treatment and tapering approach into the initial conversation. Most pediatric SSRI courses are bounded; ADHD treatment often situational; bipolar and severe OCD often longer-term.

Selected references for further reading

The trials cited above (CAMS, TADS, POTS, TORDIA, MTA, Cipriani 2016) form the core evidence base for adolescent psychopharmacology in current practice. AACAP practice parameters and AAP/GLAD-PC guidelines provide consolidated clinical guidance. Maintenance of familiarity with the original trials supports both clinical decision-making and informed consent conversations with adolescents and families.